BEERSE, Belgium, June 11, 2018 /PRNewswire/ --
FOR MEDICAL AND TRADE ONLY
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that ten company-sponsored abstracts will be presented at the Annual European Congress of Rheumatology (EULAR 2018) in Amsterdam, Netherlands being held on 13-16 June.
Data from the rheumatology portfolio includes latest research findings on Stelara(R) (ustekinumab), an anti-interleukin (IL)-12/23 monoclonal antibody, in the treatment of active systemic lupus erythematosus (SLE)*. Janssen will present two abstracts which evaluate the efficacy and safety as well as the SLE Disease Activity Index 2000 (SLEDAI-2K) and SLEDAI-2K Responder Index-50 (SRI-50) responses of ustekinumab in patients with SLE. [1],[2]
Presentations of note for guselkumab include three abstracts from the Phase 2 study of guselkumab in active psoriatic arthritis patients**. Data on dactylitis and enthesitis, as well as long-term follow-up on efficacy and safety will be presented.[3],[4],[5]
"At Janssen we are committed to addressing the unmet needs of people living with rheumatic diseases today and in the future. We're looking forward to presenting the latest data from our portfolio and pipeline at this prestigious conference," comments Wim Noel, Medical Affairs Director Rheumatology, EMEA at Janssen-Cilag NV.
Abstracts of interest
The following abstracts will be presented at EULAR as an exchange of scientific and clinical information (all times, CEST):
TREMFYA(R) (guselkumab) Abstract No. Title Date/Time OP0166[6] Comparative evaluation of cellular Oral presentation and molecular changes associated with Thursday June 14; response to selective IL-23 blockade 10:15-11:45 vs dual IL-12/23 blockade in psoriasis skin OP0308[5] Efficacy and safety results of Oral presentation guselkumab in patients with active Friday June 15; psoriatic arthritis over 56 weeks 10:15-11:45 from a Phase 2a, randomized, double-blind, placebo-controlled study SAT0322[3] The effect of guselkumab on Poster presentation dactylitis: results from a Phase 2 Saturday June 16; study in patients with active 10:30-12:00 psoriatic arthritis SAT0344[4] The effect of guselkumab on Poster presentation enthesitis: results from a Phase 2 Saturday June 16; study in patients with active 10:30-12:00 psoriatic arthritis AB0912[7] Two-year efficacy and safety of Published in Abstract guselkumab for treatment of Book moderate-to-severe psoriasis: Phase 3 VOYAGE 1 trial STELARA (ustekinumab) Abstract No. Title Date/Time FRI0339[1] SLEDAI-2K Responder Index-50 is Poster presentation effective in demonstrating partial Friday June 15; response in a Phase 2, randomized 11.15-13:30 placebo-controlled study of ustekinumab in patients with active systemic lupus erythematosus FRI0303[2] Efficacy and safety of ustekinumab in Poster presentation and patients with active systemic lupus guided tour erythematosus: results of a Phase 2, Friday June 15; randomized placebo-controlled study 11.45-13:30
About systemic lupus erythematosus (SLE)
Lupus is a chronic, inflammatory autoimmune disease that can affect many different body systems, including joints, skin, heart, lungs, kidneys and brain.[8] SLE can range from mild to severe and is characterised by inflammation of any organ system including kidneys, nervous system and brain.[9] The disease most often affects women and disproportionately affects women of African American, Hispanic, Asian and Native American descent compared to Caucasian women.[10] Incidence rates vary across European countries, ranging from 2.2 cases/100,000 in Spain to 5 cases/100,000 in France.[11] Lupus is estimated to affect at least 5 million people worldwide.[12]
About psoriatic arthritis
Psoriatic arthritis is a chronic immune-mediated inflammatory disease characterised by both joint inflammation and the skin lesions associated with psoriasis.[13] It is estimated that one third of the 125 million people who are living with psoriasis worldwide; over a third of whom will also develop psoriatic arthritis.[14] The disease causes pain, stiffness and swelling in and around the joints and commonly appears between the ages of 30 and 50, but can develop at any time.[13] Though the exact cause of psoriatic arthritis is unknown, genes, the immune system and environmental factors are all believed to play a role in the onset of the disease.[15]
About psoriasis
The most common form of psoriasis is plaque psoriasis, usually resulting in areas of thick, red or inflamed skin covered with silvery scales which are known as plaques.[16] The inconsistent nature of psoriasis means that even when plaques appear to subside, many patients still live in fear of their return.[17]
Psoriasis can cause great physical and psychological burden. A study comparing psoriasis to other prominent conditions found its mental and physical impact comparable to that seen in cancer, heart disease and depression.[18] Psoriasis is also associated with several comorbidities including psoriatic arthritis, cardiovascular diseases, metabolic syndrome, chronic obstructive pulmonary disorder (COPD) and osteoporosis.[19] In addition, many individuals are faced with social exclusion, discrimination, and stigma because of their disease.[17]
About ustekinumab[20]
(CONTINUA)
